Pagoclone

Pagoclone is a type of anxiolytic drug that is part of the cyclopyrrolone family. It was developed by a pharmaceutical company called Pfizer and is known for its unique ability to treat stuttering and panic disorder.

History

Pagoclone was initially developed by Pfizer in the late 1990s as a potential treatment for anxiety and panic disorders. However, it was not approved by the FDA due to concerns about its side effects. Despite this, it has been used in clinical trials for the treatment of stuttering and has shown promising results.

Pharmacology

Pagoclone is a non-selective GABA_A receptor partial agonist, which means it works by increasing the activity of GABA, a neurotransmitter in the brain that helps to reduce anxiety and promote relaxation. It is similar in structure to other cyclopyrrolone drugs such as zopiclone and eszopiclone, but it has a different pharmacological profile.

Clinical uses

While pagoclone is not currently approved for any medical uses, it has been studied in clinical trials for the treatment of stuttering. In these trials, it has been shown to significantly reduce the frequency of stuttering episodes and improve overall speech fluency. It has also been studied for its potential use in the treatment of panic disorder, but further research is needed to confirm its efficacy and safety in this area.

Side effects

The most common side effects of pagoclone include dizziness, nausea, and fatigue. In rare cases, it can also cause more serious side effects such as hallucinations, memory loss, and dependence.

See also

• Anxiolytic
• Cyclopyrrolone
• GABA_A receptor
• Pfizer
• Stuttering
• Panic disorder

• 
  Pagoclone
• 
  Pagoclone synthesis